Podcasts about endometrial cancer

Featuring perspectives from Ms Kathryn M Lyle, Dr Ritu Salani, Ms Jaclyn Shaver and Dr Brian M Slomovitz, including the following topics: Introduction: Overview of Endometrial Cancer (0:00) First-Line Therapy for Advanced or Recurrent Endometrial Cancer (11:01) Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced Endometrial Cancer (39:09) Novel Investigational Strategies for Newly Diagnosed Advanced Endometrial Cancer (1:00:15) Incidence and Management of HER2-Positive Endometrial Cancer (1:17:52) NCPD information and select publications  

Dr Ritu Salani and Dr Brian Slomovitz and nurse practitioners Ms Kathryn Lyle and Ms Jaclyn Shaver discuss datasets guiding treatment decision-making for patients with endometrial cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice

In this two-part series host Jonathan Sackier is joined by Bradley Monk, a pioneering figure in gynaecologic oncology. In Part 1, they discuss key updates from the European Society of Gynaecological Oncology (ESGO) Congress, including the updated ESGO-ESTRO-ESP endometrial cancer guidelines and the latest results from the KEYLYNK-001 study in ovarian cancer. With reflections from his three-decade career, Monk provides actionable takeaways for clinicians and researchers alike. Stay tuned for Part 2, where they delve into insights from SGO 2025.  Timestamps:  00:00 - Quickfire questions 04:55 - Career milestones 07:10 - ESGO 2025 standout sessions 09:52 - KEYLYNK-001 trial & takeaways 13:52 - New endometrial cancer staging   

Why are Black women are less likely to survive endometrial cancer? It's a deep-seated inequality, and Dr Kemi Doll has been treating patients and studying it for years. She explains what endometrial cancer is, why this lethal disparity exists, and why she thinks Black women are the ‘canary in the coal mine' in women's health. Show Notes:More about Dr Kemi Doll - https://www.uwmedicine.org/bios/kemi-dollMore about endometrial cancer - https://www.cancer.org/cancer/types/endometrial-cancer/about/what-is-endometrial-cancer.htmlSubscribe to our newsletter for more on this episode: https://overlookedpodcast.kit.com/e4b85028b6Want more Overlooked? Listen to this episode about mapping the ovaries next: https://overlooked.simplecast.com/episodes/mapping-the-ovaries-with-dr-kathleen-e-oneill LIKE WHAT YOU HEAR? Support the show by:- Leaving a review on Apple, Spotify, or wherever you're listening.- Becoming a Patron - Overlooked is on Patreon, where you can and get rewards like merch, the ability to send in questions for expert guests, and a 'backstage pass' to the show. New to Overlooked? Welcome. Overlooked was launched in 2023 to tell the story of ovarian cancer through one woman's story. In 2024 the show started to cover other overlooked topics in women's health - and there are many. The show is hosted by Golda Arthur, an audio journalist and producer. EMAIL US: hello@overlookedpod.com FOLLOW US:Instagram https://www.instagram.com/overlookedpod/LinkedIn https://www.linkedin.com/company/105541285/admin/dashboard/ LEARN MORE: https://overlookedpod.com/ DISCLAIMER What you hear and read on ‘Overlooked' is for general information purposes only and represents the opinions of the host and guests. The content on the podcast and website should not be taken as medical advice. Every person's body is unique, so please consult your healthcare professional for any medical questions that may arise.

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCsOn-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicityCombination Therapy Considerations: Challenges in combining ADCs with immunotherapy or chemotherapy due to overlapping toxicities and tolerability concerns Presenters:Catherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasZev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaLink to full program: https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above. 

Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics: Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00) Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38) CME information and select publications

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers.Mechanisms of action of ADCs: how ADCs selectively deliver potent chemotherapy to tumor cellsClinical data across tumor types: highlights from recent trials with trastuzumab deruxtecan and exploration of emerging data on agents such as disitamab vedotinChallenges and future directions:key considerations for combining HER2-targeted ADCs with immunotherapy or chemotherapy, and sequencing ADC therapiesPresenters:Catherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasZev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaLink to full program:https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above. 

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how to test for HER2 in advanced cancers and how these tests guide therapy selectionVariability in HER2 Expression Across Tumor Types: Insights into the heterogeneity of HER2 expression and amplification in different cancersChallenges in Standardizing HER2 Testing: The complexities of scoring and testing HER2 in different cancers and institutions, and the need for better harmonization of guidelines and approachesPresenters:Zev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceCatherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaLink to full program:https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above. 

Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Donal Brennan, a leader in gynaecological oncology and Principal Investigator at Systems Biology Ireland. Together, they discuss advances in ovarian cancer surgery, including cytoreductive techniques and hyperthermic intraperitoneal chemotherapy (HIPEC), as well as the impact of obesity on cancer development and treatment strategies.  Brennan also shares insights on platinum resistance in ovarian cancer, the FeMMe trial exploring weight loss as a treatment for endometrial cancer, and his innovative approaches in surgical oncology.  This episode is essential listening for anyone interested in the future of cancer treatment, innovation in surgery, and patient-centred care.  Timestamps:  (00:00) - Introduction  (01:51) - Music debates in the surgical theatre  (03:42) - Evolution of surgical techniques in ovarian cancer  (06:32) - The importance of early diagnosis  (08:18) - State-of-the-art on HIPEC in gynaecological oncology  (11:36) - Obesity's impact on cancer diagnosis and treatment  (19:06) - The FeMMe trial: weight loss as a treatment for endometrial cancer  (21:47) - Platinum resistance in ovarian cancer and future therapies  (28:14) - Innovation in gynaecological surgery and medical technology  (29:53) - The COMFORT trial: mental health and cancer treatment  (33:24) - Biggest challenges and opportunities in gynaecological oncology research  (37:42) - Three wishes for the future of cancer treatment 

Joining us on Well Said is Dr. Jill Whyte, a gynecologic oncologist at Northwell Health and Assistant Professor at the Donald and Barbara Zucker School of Medicine and Sudhi Trye, an OBGYN Attending with the Northwell Health Physician Partners and Assistant Professor Zucker School of Medicine. They will be helping us understand the ins and […]

About 61,000 cases of endometrial cancer are expected to be diagnosed in the U.S. this year. Our guest is Dr. Sharyn Lewin, Director of Gynecologic Oncology at the Holy Name Medical Regional Cancer Center in Teaneck, NJ to talk about diagnosis and treatment options, and the organization she founded to fight women's cancers, the Lewin Fund. For more, visit thelewinfund.org.

HEALTH NEWS   ·         Mediterranean plants show promise for cardiovascular disease treatment ·         Walking away from depression: How daily steps improve mental health ·         Phase II trial finds fish oil reduces prostate cancer progression in men undergoing active surveillance  ·         Hot tub therapy offers hope for people with type 2 diabetes ·          Study: Sugary Drinks Increase Risk of Endometrial Cancer in Women ·         Transcendental Meditation most effective at treating PTSD in largest review to date 

Dr Kathleen N Moore shares her perspectives on the evolving therapeutic landscape for patients with gynecologic cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Francesco Fanfani to discuss secondary cytoreductive surgery in endometrial cancer. Dr. Francesco Fanfani serves as an associate professor in gynecologic oncology at Fondazione Policlinico Universitario Agostino Gemelli, IRCCS in Rome, Italy. Highlights: Secondary cytoreductive surgery with complete gross resection, has the potential to offer significant survival benefits in recurrent endometrial cancer patients. Age

As a fitness and health professional, Dale considered herself to be in excellent health, so when she received an endometrial cancer diagnosis, it was totally unexpected. Her initial reaction was fear and so she followed the recommended conventional treatment, including surgery and chemo. Dale felt in her heart that this was not the way, and the success rate for survival was low, that when treatment was over she followed her instincts and went to Hope 4 Cancer. Dale discovered Radical Remission and that fueled her to continue her healing journey trusting her instincts and using natural methods that others had used successfully. Dale researched like her life depended on it, because it did. Learning about different therapies she could do and understanding cancer as a metabolic disease has helped her get into remission and she plans on staying there! To connect with Dale visit her at.... livebeyondcancer.com Facebook: DaleCWeber Email: yourguidetohealing@gmail.com or daleweber10@gmail.com ______ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram  YouTube

- Overview of Endometrial Cancer, Including Diagnosing and Staging - Current Standard of Care - New Treatment Approaches - New Treatment for Metastatic Endometrial Cancer - The Role of Precision Medicine, Targeted Treatments, and Immunotherapy - The Important Role of the Pathologist - Genetic and Biomarker Testing - Clinical Trials: How Research Increases Treatment Options - Managing Treatment Side Effects, Symptoms, Discomfort and Pain - The Benefits of Communicating with Your Health Care Team - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, and Quality-of-Life Concerns - Questions for Our Panel of Experts

Send us a textGrab your trainers, your dog lead or a pumpkin spice latte and join us for some free CPD as we have another relaxed round up of recent Red Whale primary care Pearls of wisdom.  October was another bumper month of information, meaning that we can't possibly squeeze it all into one handy sized episode, so in the first of two episodes this month, Ali and Nik discuss: HRT, bleeding and endometrial cancer... Have you had more phone calls and e-consults? Recent media coverage has made this a topic that we all need to know about.Big changes in the UK vaccination schedules. We help you to update and refresh your knowledge in this fast-changing area. Listen as soon as you can to ensure you have full access to all the free resources. The rest of the Pearls from October will be covered next week along with a new best intentions story to put a smile on your face.Links:Sign up for GP trainee essentialsBMS – management of unscheduled bleeding on hormone replacement therapy Effective Approaches to Combat Vaccine Hesitancy Send us your feedback podcast@redwhale.co.uk or send a voice message Sign up to receive Pearls here. Pearls are available for 3 months from publish date. After this, you can get access them plus 100s more articles when you buy a one-day online course from Red Whale OR sign up to Red Whale Unlimited. Find out more here. Follow us: X, Facebook, Instagram, LinkedInDisclaimer: We make every effort to ensure the information in this podcast is accurate and correct at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, check drug doses, side-effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in this podcast....

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Alessandro Santin to discuss Sacituzumab Govitecan (TROPiCS—03) in Advanced Endometrial Cancer. Dr. Alessandro D. Santin, a native of Italy, graduated with honors from the University of Brescia, Italy and received his postgraduate training in Obstetrics & Gynecology at the same University. He served a fellowship in Gynecologic Oncology at the University of California, Irvine and an International Fellowship in the Division of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, Arkansas. Dr. Santin joined the faculty in the Section of Gynecologic Oncology in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale University as Professor as of July 2008. Dr. Santin has more than 400 original research and peer-reviewed publications including multiple review articles and book chapters and he has written extensively on various topics, including cancer of the ovary, endometrium and cervix as well as on tumor immunology and immunotherapy. Dr. Santin's clinical interests include the use of immunotherapy in ovarian, cervical and endometrial carcinoma patients with disease resistant/refractory to standard treatment, therapeutic vaccines against Human Papillomavirus (HPV) infected genital tumors, and the development of personalized treatment modalities including monoclonal antibodies and antibody-drug-conjugates (ADC) against chemotherapy resistant gynecologic tumors. Highlights: In the TROPiCS-03 trial Sacituzumab Govitecan demonstrated encouraging clinical activity in recurrent endometrial cancer patients in progression after chemotherapy and immune check point inhibitors Sacituzumab Govitecan toxicity profile was manageable with only 5% of patients discontinuing treatment due to TRAEs TROP-2 protein was expressed in over 90% of endometrial cancer patients enrolled in the TROPiCS-03 trial and showed limited correlation with efficacy to Sacituzumab Govitecan

Drs. Dietrich and Holloway continue sharing their insights into the pivotal role of HER2 positivity in gynecologic cancers. They discuss how HER2, a well-known biomarker in breast cancer, is increasingly recognized for its significance in other gynecologic malignancies, including ovarian and endometrial cancers.

Drs. Dietrich and Holloway share their insights into the pivotal role of HER2 positivity in gynecologic cancers. They discuss how HER2, a well-known biomarker in breast cancer, is increasingly recognized for its significance in other gynecologic malignancies, including ovarian and endometrial cancers.

On tomorrow night's show, we'll be highlighting endometrial cancer with Kristen Foreman, an endometrial cancer survivor and Dr. Sharyn Lewin, Director of Gynecologic Oncology at the Holy Name Medical Regional Cancer Center in Teaneck, NJ. After that, I'll have a generic interview focused on allergies related to Halloween candy with Dr. S. Shahzad Mustafa and Margaret, the mother of a 16-year-old who is severely allergic to peanuts and tree nuts.

Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of gynecologic oncology, focusing specifically on endometrial cancer. Hosted by Drs. Rohit and Rahul Gosain, this episode features Dr. Shannon Westin, a Professor of Gynecology, Oncology, and Reproductive Medicine at the MD Anderson Cancer Center. In this episode, we explored: •⁠  ⁠The different histologies of endometrial cancer, including endometrioid, serous, clear cell, and undifferentiated types. •⁠  ⁠The evolving landscape of molecular classification and its impact on treatment decisions. •⁠  ⁠The current treatment paradigms for early-stage and advanced endometrial cancer, including the role of surgery, chemotherapy, and immunotherapy. •⁠  ⁠The significance of NGS (Next-Generation Sequencing) testing in identifying actionable mutations, such as MSI-high tumors and HER2-positive cancers. •⁠  ⁠The latest advancements in adjuvant therapies and the potential of combining chemotherapy with immunotherapy. Whether you're a healthcare professional or simply interested in the latest developments in cancer treatment, this episode is packed with valuable insights and expert opinions. Don't forget to like, subscribe, and check out our other discussions focusing on ovarian cancer and more! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Dr. Shannon Westin and her guest, Dr. Brian  Slomovitz discuss the article “Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors” recently published in the JCO and presented at the 2024 International Gynecologic Cancer Society. TRANSCRIPT The guest's disclosures can be found in the transcript.  Dr. Shannon Westin: Hello, and welcome to another episode of JCO After Hours, the podcast where we get in depth on manuscripts and literature published in the Journal of Clinical Oncology. I'm your host, Shannon Westin, gynecologic oncologist and JCO Social Media Editor by trade. I am thrilled because we are going to be talking about gynecologic cancer today. So, this is my jam. And specifically, we're going to be talking about a manuscript that's a simultaneous publication in the Journal of Clinical Oncology and presented at the Annual Meeting of the International Gynecologic Cancer Society on October 16, 2024. And this is “Pembrolizumab or Placebo, Plus Adjuvant Chemotherapy, With or Without Radiotherapy for Newly Diagnosed High Risk Endometrial Cancer: Results in Mismatch Repair Deficient Tumors.” This is affectionately the KEYNOTE-B21 trial, also known as the GOG-3053 trial and the ENGOT-en11 trial. And we are joined today by the primary author in this manuscript, Dr. Brian Slomovitz, who is the Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida, and the clinical trial advisor in uterine cancer for the Gynecologic Oncology Group foundation. Welcome, Brian. Dr. Brian Slomovitz: Hey, thanks, Shannon, so much. It's a pleasure to be here. And thanks for giving us the opportunity to discuss this trial. Dr. Shannon Westin: Yes, it's a great trial and I'm so excited to talk about it. And I think we'll start just because this is a broad group that listens to this podcast, they're not all GYN oncologists, experts like yourself, so can you just level set a little bit and speak a bit about the incidence and mortality of endometrial cancer overall and the recent trends in this disease? Dr. Brian Slomovitz: Yeah, sure. So, and it is nice to speak about gynecologic cancers, as we know, endometrial cancer was and still is the most common of all gynecologic cancers. The numbers are going up. Right now, there's about 65,000 to 70,000 cases each year in the US diagnosed with endometrial cancer. The numbers are going up. A lot of its obesity related, some other factors, but as the population gets less healthy, those are some of the risk factors for the disease. The thing that, however, is quite surprising is that we're seeing the deaths due to endometrial cancer going up as well, while for other diseases, we're making slow, steady steps to try to decrease the mortality we're actually seeing an increase in mortality. And the most discouraging point, Shannon, as you know is the number of deaths from endometrial cancer is going to outnumber the number of deaths from ovarian cancer if it hasn't done it already. I mean, now's the time. So, we really need to come up with better treatment strategies to everything to decrease the incidence of disease, to help with prevention, but for those poor women who are diagnosed, to come up with better treatment options so we don't have to keep this increasing trend in mortality. Dr. Shannon Westin: Absolutely. And I think some of that is related and we don't need to get on a soapbox here, but the amount of funding that goes towards research in endometrial cancer, and of course you, you have been leading the way and really trying to get a ton of trials in this space and getting our industry partners and our government partners to really support this. So really just commending you on how much you've worked on, on this area. And to that end, we've had a huge renaissance with immunotherapy and endometrial cancer, a lot of really big trials. Why don't you give the audience a rundown of where, so far, this seems to be best utilized for people with endometrial cancer? Dr. Brian Slomovitz: Thanks for that. And as you sort of alluded to, it's been a revolution, really, with immunotherapy. We started off at immunotherapy looking at microsatellite instability or the dMMR patients. What we found is similar to other disease sites in the second and third line setting that we saw good activity with the single agent checkpoints, pembrolizumab dostarlimab, that's based on the earlier KEYNOTE data and the GARNET trial. Really, a landmark study in the second line was Vicki Makker and her colleagues put pembrolizumab and lenvatinib combination for those patients with the cold tumors. Not the dMMRs or MSI Highs, but the proficient mismatch repair. And that study in a second line setting found that it was better than chemotherapy for an overall survival advantage. So right there, we know that it works in the second line setting in the dMMR population, and we got an indication in the PMR population saying that immunotherapy works in all women with endometrial cancer at some point, then we really had the groundbreaking trials. And Shannon, thank you. You are the leader on one of the four trials that happened, to DUO-E, AtTEnd, GY018 and RUBY trial, all very similar studies showing that the combination of immunotherapy with chemotherapy in the first line, metastatic or recurrent setting had a better outcome for patients than if given chemotherapy alone. That actually led to amazing things. We had three of those drugs have FDA approvals, pembrolizumab for all comers, dMMR and PMMR in the first line metastatic setting with chemotherapy; Dostarlimab, PMR, dMMR in the first line or metastatic with chemotherapy. And Shannon, in your study, I think we still have to learn a lot from your study. DUO-E, chemotherapy plus minus dostarlimab. And you also added a PARP inhib, and those patients with a PARP did better. So I'm really looking forward to your data, to the subgroup analysis to figure out which of those patients, depending on the biomarker, do better with PARP therapy. And right now, you have a dMMR FDA indication. But who knows? The future is really exciting to see- to be splitters, not lumpers. And I really want to see how that data pans out. And so that's how it came into the first and second line setting and that led us really to come up with the idea for this trial to put it into the adjuvant setting. Dr. Shannon Westin: Right. And so, I think this would be really important because we're so ingrained in this. We see this on the day to day. Can you kind of tease out a little bit what's different about those patients that would be treated in that advanced recurrent setting versus the patients that would be potentially treated in this B21 study? Dr. Brian Slomovitz: Yeah, so the first step, we demonstrated the efficacy in patients that really the treatment options were an unmet need. In the second line setting, we didn't have good treatment options. Those are the patients with measurable disease, with symptomatic disease giving immunotherapy. And not only did we see the efficacy, which was better, but we also were able to give it with limiting the side effects as seen with chemotherapy, which is nice. And then we know that the first line therapy, traditionally for endometrial cancer with carboplatin paclitaxel, response rates about 50%, progression free survival about a year, really something that we needed to improve upon. So, adding immunotherapy to the platinum backbone therapy really demonstrated an advantage. But now what we want to do is we want to see if we could prevent, in the high-risk patients, those without disease, what can we do to help prevent the disease from recurring and help patients live longer without really the need for really lifesaving types of treatments? We want to prevent it from recurring. Dr. Shannon Westin: Yeah, I think that's essential. We know that if we can sit on that prevention side and kind of invest all the time and effort that we need to upfront, that really does yield the longer survival. So why don't you just walk through the overall design of this trial, please? Dr. Brian Slomovitz: Yeah. So, this was an all-comers trial, meaning in individuals that had high risk endometrial cancer, high risk for recurrence, that included, in endometrial cancer, we have aggressive histologic subtypes, serous histologies, clear cell histologies, any stage, as long as there was some myometrial invasion. We also, for the first time, included patients looking at the molecular subclassifications. So, if there was a P53 mutation and they were stage 1 with myometrial invasion, they were included. And then in all comers, any patients with stage 3 or up to 4a disease, as long as the surgery was for a curative intent, and they had no residual disease after surgery, then they were allowed to enroll into this trial. One of the things is that this is the first time we've done an adjuvant trial this large. I think one of the reasons that helped us succeed in doing a trial like this is that we left radiation as investigator's choice, because a lot of times going into a trial like this, people feel strongly, we know our radiation oncology colleagues, rightfully so, feel that radiation could help prevent disease from coming back. And we also have the camp that says they don't need radiation. We took that question out of this study. We let investigators decide whether or not they're going to get radiation. It was for patients to get chemotherapy, who are going to normally get chemotherapy for their high-risk disease and randomize them to chemotherapy plus placebo or chemotherapy plus pembrolizumab, a PD-1 inhibitor, in order to see if we could prevent the disease from coming back. Dr. Shannon Westin: And the primary results of this study were just presented at ESMO and published in the Annals of Oncology. Can you give us just a quick overview of what that was, what they found? Dr. Brian Slomovitz: Yep. So, we enrolled 1100 patients. The primary objective of the study was to look at the ITT population, progression free survival and overall survival. And the overall study was negative. Okay, so the hazard ratio in the ITT population was 1.02, not demonstrating a benefit of adding pembrolizumab in this population. I would say disappointing, but at the same point, something that we could really learn a lot from and somewhere that we know that in the whole population, we need to come up with better strategies to help prevent recurrence of disease, better adjuvant treatment strategies. But there's also information that we learned from this trial and that we're reporting on that we're actually super excited about and we feel may be game changing. Dr. Shannon Westin: Yeah. So, let's go to that. This is the good news. Your manuscript in the JCO, thank goodness you published it here, was focused on that subset of mismatch repair deficient. So, tell us what you found. Dr. Brian Slomovitz: So, in this study, we found that the first stratification factor was dMMR versus pMMR. Now, in the pMMR group, those patients had further stratification factors, but dMMR by itself was a stratification factor. Amongst those patients that had dMMR tumors, we found the hazard ratio to be 0.31 benefiting those patients who received pembrolizumab in the adjuvant setting. Really something that when we look at the treatment studies, the GY018s, the RUBYs, the atTEnds, the DUO-Es, in a dMMR setting, we see a similar hazard ratio of 0.3, 0.4. But to get that hazard ratio, which was statistically significant, obviously, is something that we were quite pleased with and something that we felt was worthy of reporting further. I will say it was a pre-specified endpoint. We didn't allocate alpha to it. So, at the beginning, it was a pre-specified endpoint, but at the same time even though we didn't specify alpha towards that outcome, it still, we feel is clinically meaningful and can definitely add to affect the standard of care and the management of these patients. Dr. Shannon Westin: Yeah. I'm very intrigued to see what kind of people do with this. It makes sense, mechanistically, it makes sense if there was a population that was going to benefit, if not everybody does, this is the group that will. I mean, do you feel like there's enough data? What are you going to do? FDA approval aside, obviously, those kinds of things. But how do you feel about this? Is this something you're going to offer to your patients? Dr. Brian Slomovitz: The first answer is yes. I think it's something that I would like to offer my patients. As you know, we need one of two things: we either need an FDA approval or for a lot of our payers required to be in the NCCN listings. I don't serve on the committee. I have no influence on NCCN. I'm excited to see how they'll respond to not only the Annals article, but obviously in today's release of the JCO article, I hope that they'll look upon it favorably. It's a drug that we're used to giving. Pembrolizumab, we have a lot of experience with it. It's interesting. We didn't see any new safety signals, Shannon. Dr. Shannon Westin: Yeah, I was going to ask - that's great. Dr. Brian Slomovitz: There was nothing, nothing additional that we found in this trial. So, I feel that it can definitely improve the outcome of those patients, in my view, with high risk for recurrence, treating pembrolizumab in this setting. Dr. Shannon Westin: Yeah, I think it's important, of course, to look at the safety. What about quality of life? Any new findings there? Dr. Brian Slomovitz: Yeah, we did that quality of life as part of the phase 3 trial. No difference between the two arms. No difference between the two arms. When we looked at a couple of the other analyses, we found that the benefit is the same on stage 3, 4 tumors. We saw that the benefit was there as well. So, there were less patients in the stage 1, 2 group. But I think really, for all comers, for the patient population, I would definitely consider giving pembrolizumab, again, for those patients with a deficient mismatch repair. Dr. Shannon Westin: It's really exciting, and I think you mentioned some of the statistical limitations. Anything else that gives you pause about the study or things you wish you did better? I know we always like to armchair quarterback ourselves after we do these kinds of studies. Dr. Brian Slomovitz: Yeah, it's interesting. When we designed the study years ago, we used the best information we had at that time to come up with the study design, and we're happy with it, and we really don't think that we could have done it much better. I should say, this was a great partnership that we had here between the GOG, ENGOT and with sponsor Merck, Toon Van Gorp was the lead PI of the global trial. When he gave me the good opportunity to present it at the IGCS and to be the lead author on this, it was really a great partnership. And when we came up with a trial years ago, it was the best trial that we thought at that time. And based on the information now, I think it's really something that we're excited about these results, even though the overall trial was negative. Dr. Shannon Westin: Yeah, I agree with you. I think it's interesting, it's informative to think about, “Well, what would we do now or then if we knew what we knew now?” But still, you design the trial the best way you can. I think the results are super intriguing. I'm hopeful at the way they'll be reviewed. I agree I don't have any inside information about the NCCN committee, but I do hope that they'll consider the overarching data to support immunotherapy and mismatch repair deficiency and the findings of this study. And then I guess the last question I would just ask, as you're an expert here, what are you looking forward to seeing coming next in this space? What's the stuff you're intrigued about in endometrial cancer? Dr. Brian Slomovitz: I think, Shannon, you and I have talked about this for a while. I think we're getting really close to eliminating chemotherapy for some of the patients who suffer from this disease. So, I'm not sure if we'll do a follow up to this trial, but I think a logical type of follow up would be to see: what if we just took away chemotherapy altogether and we did pembro in the adjuvant setting, pembrolizumab versus chemotherapy? We don't have that trial in the adjuvant setting, but actually, we completed accrual of that trial in the recurrent setting and we're anxiously awaiting those results. That's KEYNOTE-C93, where in the dMMR population we studied pembrolizumab versus carboplatin paclitaxel. How those results may translate into this setting, I'm not sure. Right now, it's exciting what we have, but yeah. And I think future is bright for this. Just to highlight, in the two arms, there's 140 patients approximately in each arm; there were 25 recurrences in those patients who received placebo. Only eight recurrences in those that received pembrolizumab. Really, when we talk about numbers, it's really remarkable and it shows you the benefit it really had on the patients. Dr. Shannon Westin: Well, this was great. It flew by, as it always does when I'm having conversations with you. I just really want to thank you again for taking the time to share your knowledge with our listeners. Dr. Brian Slomovitz: Thanks, Shannon. Dr. Shannon Westin: And listeners. Thank you all for taking the time to hear about endometrial cancer. Again, this was “Pembrolizumab or Placebo, Plus Adjuvant Chemotherapy, With or Without Radiotherapy for Newly Diagnosed High Risk Endometrial Cancer Results in Mismatch Repair Deficient Tumors.” And this was the JCO After Hours. If you loved what you heard, please check out wherever you get your podcast to see what else we have to offer. Have an awesome day.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.        

Nadeem Abu-Rustum bio: Dr. Abu-Rustum is a board-certified gynecologic oncologist who specializes in the surgical treatment of gynecologic cancers at Memorial Sloan Kettering Cancer Center. He is also a professor of obstetrics and gynecology at Weill Cornell Medical College. Dr. Abu-Rustum has a special interest in minimally invasive surgery (laparoscopy) for the treatment of cancerous and noncancerous diseases of the female reproductive system, and his clinical research focuses on surgical therapy for gynecologic cancers and innovative surgical approaches to treating gynecologic disorders. Christian Dagher bio: Christian Dagher is a former research fellow at Memorial Sloan Kettering, and current OBGYN resident at the University of Pennsylvania. He holds a master's degree in clinical epidemiology and health-services research from Weill-Cornel. Before moving to the US, he completed an OBGYN residency at the American University of Beirut and is interested in studying survival biomarkers in endometrial cancer.  Highlights: The 2023 FIGO staging system for endometrioid endometrial carcinomas included the extent of lymphovascular invasion as a determinant of stage. The new staging system, groups tumors with no lymphovascular space invasion and those with focal invasion (

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

Editor’s choice: The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma Editorial: Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment? Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing: Mohamed Elshaikh, MDBeriwal Sushil MD

Do you know the best approaches to managing patients with endometrial cancer in the adjuvant setting?   Credit available for this activity expires: 9/24/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001649?ecd=bdc_podcast_libsyn_mscpedu

Lisa Tarantino, HealingStrong Group Leader shares her story, which began with being post-menopausal. Through advocating for a biopsy for herself, she found out she was diagnosed with stage 3c endometrial cancer⁣ in 2017.After feeling blind-sided, she followed the lead of her doctors and went forward with surgery, which began a series of surgeries and chemo to follow. Despite the beginning of her journey approach, she knew God could help her more and instinctively she needed to change some emotional aspects in her life. She refused radiation and realized she wanted to take a different direction. Lisa's story is inspiring, encouraging and one that will bring you HOPE, and she came to become a part of HealingStrong. This episode is a reminder that our steps are ordained and God is in the details. CONTACT:St. Lucie, Florida HealingStrong Grouplisacancercoach@gmail.comHealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please consider supporting our mission by becoming a part of our Membership Program, as a monthly donor.When you do, you will receive additional resources such as: webinars, access to ALL our past and most recent conference videos, downloadables and more, as a bonus.To learn more, head to the HealingStrong Membership Program link below: Membership Program

The early symptoms were not clear. But after feeling “off” for a few days following a trip abroad, Candice took herself to the ER. Soon after, she was diagnosed with Stage 4 endometrial cancer. She was just 41. With the guidance and expertise of Washington University gynecologic oncologist, Dr. Premal Thaker, Candice welcomes each day, meeting it with unrelenting tenacity and spirit. Dr. Thaker shares about the rise of endometrial cancers in the U.S. (and globally) and discusses the red flag every postmenopausal woman needs to know. Listen to Candice's story and witness the powerful bond between patient and doctor with a common goal: fueling life with hope while facing cancer.    “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.    “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/cancer-types/uterus-endometrial/ https://siteman.wustl.edu/treatment/cancer-types/uterus-endometrial/symptoms-risks-and-diagnosis/ https://siteman.wustl.edu/treatment/cancer-types/uterus-endometrial/genetic-counseling-for-gynecologic-cancers/ https://siteman.wustl.edu/treatment/siteman-psychology-service/ https://getscreenednow.com/ https://siteman.wustl.edu/doctor/premal-thaker-md-ms/ https://siteman.wustl.edu/treatment/specialized-programs/gynecologic-oncology/

In this week's episode Dr Louise is joined by one of her patients, Lesley Henry, a nurse who lives in Northern Ireland. Lesley shares her experience of menopause, which started before she received a diagnosis of endometrial cancer. Her treatment for cancer led to a surgical menopause, which she found debilitating. Lesley explains she feared her brain fog and fatigue would prevent her from returning to work and from caring for her mother. A firm believer in the importance of quality of life, Lesley decided to resume taking HRT. She hopes to help other women who are going through similar experiences and shares the things that have given her the strength to make decision about her treatment and her life: I have a faith. Not everybody will have the same faith as I have, and that's fine, but I think having a faith helps. Be proactive and find support groups. Through Action Cancer I learnt about scar therapy, which has helped, plus I completed a positive living programme to learn how to re-energise and rebuild my life. Be prepared to say goodbye to the old you. She's not coming back and in a way, she needs to go. Trust in yourself and listen to your heart. You are worthwhile and your life matters. Click here to find out more about Newson Health  

Dr Tewari discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Featuring an interview with Dr Angeles Alvarez Secord, including the following topics: Front-line management of ovarian cancer (0:00) Management of relapsed/refractory ovarian cancer (20:06) Management of microsatellite instability-high/mismatch repair-deficient endometrial cancer (23:20) Management of microsatellite stable/mismatch repair-proficient endometrial cancer (33:13) Targeted therapy for gynecologic cancers (44:15) CME information and select publications

Dr Angeles Alvarez Secord from the Duke Cancer Institute in Durham, North Carolina, provides her perspectives on recent datasets from ASCO 2024 on the management of ovarian and endometrial cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayASCOOvarianEndo24).

Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.

Featuring perspectives from Dr Dana M Chase, including the following topics: Introduction: ASCO 2024 Review (0:00) Ovarian Cancer (14:29) HER2 as a Therapeutic Target (29:18) Endometrial Cancer (38:55) Cervical Cancer (51:11) CME information and select publications

Dr Dana M Chase from the David Geffen School of Medicine at UCLA in Los Angeles, California, discusses select 2023 data sets on the management of ovarian, endometrial and cervical cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gyn).

Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Mansoor Mirza and Angélica Nogueira Rodrigues to discuss recent updates on endometrial cancer in Latin America. Dr. Mirza is a highly qualified medical oncologist with expertise in Medical and Radiation Oncology, holding multiple degrees and licenses in these fields. He currently serves as the Chief Oncologist at the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark, and holds the position of Medical Director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit (NSGO-CTU). Dr. Mirza is actively involved in numerous medical societies, clinical research, and international trial collaborations, and has contributed significantly to the development of clinical protocols and guidelines for the management of various cancers. Dr. Angélica Nogueira-Rodrigues is the Founder of EVA Group, and President-elect of the Brazilian Society of Medical Oncology. She is also a Researcher and Professor at Federal University, MG, Brazil, and Chair of Gynecology at the Latin America Cooperative Oncology Group (LACOG).   Highlights:   -Detailed epidemiological data on endometrial cancer in Latin America are scant, but GLOBOCAN provides estimates for the incidence of uterine cancer within countries globally. EC is the second gyn cancer in the region, due to the burden of CC which is still the first one. It is estimated that the total number of new cases of uterine cancer in Latin America and the Caribbean will rise from approximately 33,000 in 2020 to an estimated 51,000 in 2040; -The last ten years have been marked by a radical transformation in the understanding of the molecular biology of endometrial cancer, and, including it.  or not  in FIGO staging, this discussion needs to evolve and be incorporated into clinical practice  in Latin America, as it impacts clinical decision, hereditary cancer diagnosis, among others. -The main message for young gynecological oncologists as us to create a future medicine with fewer disparities worldwide is to strive  to get access an implement the best for the patient,  avoiding protocols adapted for low-income countries which can negatively impact the clinical outcomes.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ann H. Klopp to discuss radiation alone vs chemoradiation in endometrial cancer recurrence. Dr. Ann H. Klopp is a Professor of Radiation Oncology at MD Anderson Cancer Center, the head of the Gynecologic Oncology Section and a physician-scientist specializing in the treatment of gynecologic cancers. Her research focuses on improving outcomes for women with gynecologic cancers by enhancing tumor directed immune response in combination with radiation therapy and using advanced techniques to increase precision of radiation treatment delivery. Highlights: NRG0238 compared chemoradiation to radiation alone for patients with locally recurrent endometrial cancer and found that the addition of chemotherapy did not improve progression-free survival. Radiation therapy is highly effective for treatment for local recurrences of endometrial cancer. The nuances of patients enrolled and treatment delivered are discussed.

Reviews: 2023 changes to FIGO endometrial cancer staging: Counterpoint; 2023 FIGO staging system for endometrial cancer: The evolution of the revolution Editorial: 2023 FIGO staging for endometrial cancer, a look at both sides of the coin Hosted by: Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology Featuring: Dr. Alexander Olawaiye, MD, University of Pittsburgh School of Medicine, USA Dr. David Gaffney, MD-PhD, University of Utah, USA Dr. Mario Leitao, Jr., MD, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, USA

Featuring perspectives from Dr Floor J Backes, Dr Mansoor Raza Mirza, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Brian M Slomovitz, with cases presented by Dr Eric H Lee, Dr Priya Rudolph and Dr Lyndsay J Willmott, moderated by Dr Secord, including the following topics: Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Salani Introduction (0:00) Case: A woman in her mid 60s with dementia who has peritoneal carcinomatosis with OC — Eric H Lee, MD, PhD (3:00) Case: A woman in her mid 40s with advanced OC undergoes immediate cytoreduction — Lyndsay J Willmott, MD (9:52) Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr Backes Case: A woman in her late 40s with a BRCA2 germline mutation and high-grade serous OC — Priya Rudolph, MD, PhD (26:44) Case: A woman in her mid 50s with platinum-sensitive recurrent OC who had not received a prior PARP inhibitor — Dr Willmott (33:35) First-Line Therapy for Advanced Endometrial Cancer (EC) — Dr Mirza Case: A woman in her early 60s diagnosed with endometrioid cancer presents with abdominal pain 2 years later — Dr Rudolph (49:44) Case: A woman in her early 70s with microsatellite instability-high, mismatch repair-deficient Stage IV carcinosarcoma — Dr Willmott (56:44) Current Therapeutic Options for R/R EC; Novel Investigational Strategies — Dr Slomovitz Case: A woman in her early 60s with a history of serous endometrial cancer (EC) presents with recurrent disease 2 years later — Dr Rudolph (1:12:44) Case: A woman in her late 70s with EC develops a cough 2 years after initial treatment — Dr Lee (1:19:50) Role of HER2-Targeted Therapy in the Management of Advanced OC, EC and Other Gynecologic Cancers — Dr Secord Case: A woman in her late 60s with endometrioid adenocarcinoma is admitted with abdominal distention — Dr Rudolph (1:34:55) Case: A woman in her mid 30s with mucinous adenocarcinoma of the ovary is later diagnosed with a liver metastasis — Dr Lee (1:41:02) CME information and select publications

Interview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD. Related Content: Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals

Gynecologic oncology experts Dr. Matthew Powell from Washington University School of Medicine and Dr. Amanda Fader from Johns Hopkins Hospital discuss the increasing rates of endometrial cancer along with future directions of treatments and screenings. --- SYNPOSIS First, the physicians discuss trends in endometrial cancer rates and delve into the factors driving these trends, such as the obesity epidemic and aging population. They explore the differences between endometrioid and non-endometrioid cancers, along with the impact of racial and geographic disparities. The conversation also covers advances in diagnostics and treatments—including immunotherapy and targeted therapies—and the critical need for better awareness, screening practices, and research funding to combat this public health threat. --- TIMESTAMPS 00:00 - Introduction 03:11 - Types of Endometrial Cancer 04:44 - Rising Rates and Risk Factors 08:03 - Disparities in Endometrial Cancer Care 10:37 - Symptoms and Diagnosis 13:52 - Ultrasound vs. Biopsy 16:17 - Challenges in Biopsies 20:58 - Management/Treatment Approaches 23:03 - Geographic Disparities/Access to Care 26:07 - Vaginal Brachytherapy 32:11 - Innovations in Treatment and Research 40:34 - Future Directions: Endometrial Screening 43:54 - AI in Gynecologic Oncology --- RESOURCES Beavis, A. L., Blechter, B., Najjar, O., Fader, A. N., Katebi Kashi, P., & Rositch, A. F. (2023). Identifying women 45 years and younger at elevated risk for endometrial hyperplasia or cancer. Gynecologic Oncology, 174, 98–105. https://doi.org/10.1016/j.ygyno.2023.04.019 Mirza, M. R., Sharma, S., Roed, H., Landrum, L. M., Gilbert, L., Gold, M. A., Novák, Z., Edelson, M., Meirovitz, M., Diaz, J. P., Huygh, G., Buscema, J., Pothuri, B., Eshed, H. D., Coleman, R. L., Slomovitz, B. M., Kostadinov, R., Stevens, S., Ronzino, G., & Powell, M. A. (2024). Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with Dostarlimab plus chemotherapy in the ruby trial. Journal of Clinical Oncology, 42(16_suppl), 5606–5606. https://doi.org/10.1200/jco.2024.42.16_suppl.5606 Society of Gynecologic Oncology (SGO): https://www.sgo.org/

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Koji Matsuo to discuss new FIGO staging of endometrial cancer. Dr. Matsuo is a clinician-scientist in the area of gynecologic oncology in the United States. His research interest is population-based, heath service outcome research for gynecologic malignancies. Highlights: (1) Survival effect of adjuvant therapy differed between stage IA3 and IIIA1. (2) In new stage IA3 disease, omission of adjuvant therapy had comparable overall survival compared to combination chemotherapy and external beam radiotherapy or chemotherapy alone. (3) In stage IIIA1, omission of adjuvant therapy was associated with decreased overall survival compared to chemotherapy-based approach. (4) 5-year overall survival of adjuvant therapy omission group in new stage IA3 was nearly 90%. (5) These hypothesis-generating observation suggested that treatment de-escalation of well-staged stage IA3 may not adversely affect survival.